Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
IMPAKT Breast Cancer Conference
Circulating Tumor Cells Signal Worse Survival
IMPAKT Breast Cancer Conference
June 2010, Vol 1, No 2
Brussels—A retrospective study of patients with metastatic breast cancer shows that the number of circulating tumor cells in the patient’s bloodstream prognosticates the length of their survival, information that can be used to adjust treatment at the end of life.
Read Article
Genetic Testing as Simple as 1-2-3
Genetic Testing
,
IMPAKT Breast Cancer Conference
,
Personalized Medicine
June 2010, Vol 1, No 2
Brussels—A simple genetic test using only 3 genes is among the most effective means of classifying breast cancer into the subtypes that indicate pa tients’ different prognoses and response or resistance to cancer therapies, say researchers, and this finding could allow greater use of personalized treatments in breast cancer.
Read Article
Better Targeting for Targeted Therapy
IMPAKT Breast Cancer Conference
June 2010, Vol 1, No 2
Brussels—Researchers attempting to understand why some women with human epidermal growth factor receptor 2 (HER2)–positive breast cancer do not respond to drugs designed to target this molecule have found that inhibiting the PI3K/AKT molecular pathway instead may offer greater therapeutic benefit for this group. The findings were presented at the IMPAKT [Improving Care and Knowledge Through Translational Research] Breast Cancer Conference, held May 5-8.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma